Epithelial cells are sensitive detectors of bacterial pore-forming toxins

The Journal of Biological Chemistry
Adam J RatnerJeffrey N Weiser

Abstract

Epithelial cells act as an interface between human mucosal surfaces and the surrounding environment. As a result, they are responsible for the initiation of local immune responses, which may be crucial for prevention of invasive infection. Here we show that epithelial cells detect the presence of bacterial pore-forming toxins (including pneumolysin from Streptococcus pneumoniae, alpha-hemolysin from Staphylococcus aureus, streptolysin O from Streptococcus pyogenes, and anthrolysin O from Bacillus anthracis) at nanomolar concentrations, far below those required to cause cytolysis. Phosphorylation of p38 MAPK appears to be a conserved response of epithelial cells to subcytolytic concentrations of bacterial poreforming toxins, and this activity is inhibited by the addition of high molecular weight osmolytes to the extracellular medium. By sensing osmotic stress caused by the insertion of a sublethal number of pores into their membranes, epithelial cells may act as an early warning system to commence an immune response, while the local density of toxin-producing bacteria remains low. Osmosensing may thus represent a novel innate immune response to a common bacterial virulence strategy.

References

May 1, 1992·The Journal of Membrane Biology·Y E KorchevC A Pasternak
Jan 14, 1999·The American Journal of Physiology·J A MaloneyJ R Williamson
Oct 18, 2000·Infection and Immunity·B LimbagoJ R Scott
Dec 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·B van den BlinkM P Peppelenbosch
Feb 15, 2001·The Journal of Infectious Diseases·R CockeranR Anderson
Dec 18, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Iwan WalevMatthias Husmann
Jan 10, 2002·The Journal of Clinical Investigation·Johann S BraunJoerg R Weber
Aug 27, 2002·The Journal of Infectious Diseases·Riana CockeranRonald Anderson
Jan 24, 2003·Infection and Immunity·Claudia NonnenmacherKlaus Heeg
Feb 6, 2003·Proceedings of the National Academy of Sciences of the United States of America·Richard MalleyDouglas T Golenbock
May 23, 2003·Infection and Immunity·Jeffrey G ShannonRichard F Rest
Nov 25, 2003·Nature Cell Biology·Mark T UhlikGary L Johnson
Jul 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Danielle L HuffmanRaffi V Aroian
Oct 16, 2004·The Journal of Biological Chemistry·Bernd SchmeckStefan Hippenstiel
Dec 22, 2004·The Journal of Experimental Medicine·Jin Mo ParkMichael Karin
Feb 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Adam J RatnerJeffrey N Weiser

❮ Previous
Next ❯

Citations

Nov 10, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jeffrey N Weiser
Mar 15, 2008·Nature Reviews. Microbiology·Aras KadiogluPeter W Andrew
Nov 3, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Melissa E SandersMary E Marquart
Feb 1, 2008·Molecular Biology of the Cell·Travis J WilesMatthew A Mulvey
Dec 30, 2006·The Plant Cell·Dinah QutobThorsten Nürnberger
Mar 11, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Charles Feldman, Ronald Anderson
Dec 12, 2007·Infection and Immunity·Timur O YarovinskyGary W Hunninghake
Jan 14, 2009·Infection and Immunity·Catherine L KennedyJulian I Rood
Mar 3, 2010·Infection and Immunity·Ritwij KulkarniAdam J Ratner
Dec 21, 2010·Journal of Bacteriology·Ryan RampersaudAdam J Ratner
Feb 1, 2011·Drugs·Charles Feldman, Ronald Anderson
Jan 1, 2010·Biotechnology & Genetic Engineering Reviews·Angeles Cancino-RodeznoAlejandra Bravo
Mar 28, 2008·Future Microbiology·Julie A Preston, David H Dockrell
Jul 31, 2007·Future Microbiology·Charles Feldman, Ronald Anderson
Jan 6, 2010·EMBO Molecular Medicine·Marie LittmannLaura Plant
Feb 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Asparouh I IlievFred S Wouters
Sep 7, 2007·Seminars in Immunopathology·Barbara FrecheF Gisou van der Goot
Dec 17, 2014·Virulence·Rajmohan Rajamuthiah, Eleftherios Mylonakis
Jun 15, 2011·Differentiation; Research in Biological Diversity·Isaiah G Schauer, David R Rowley
Aug 25, 2015·Biochimica Et Biophysica Acta·Laura C Ristow, Rodney A Welch
Jul 6, 2010·Peptides·Helena PortaAlejandra Bravo
Dec 31, 2009·Insect Biochemistry and Molecular Biology·Angeles Cancino-RodeznoAlejandra Bravo
Jun 6, 2009·Biochemical and Biophysical Research Communications·Nicole KloftMatthias Husmann
May 16, 2009·Current Opinion in Cell Biology·Mirko BischofbergerF Gisou van der Goot
May 17, 2008·Experimental and Molecular Pathology·Travis J WilesMatthew A Mulvey
Oct 21, 2015·Seminars in Cell & Developmental Biology·Eduard B Babiychuk, Annette Draeger
Mar 10, 2007·Biochemical and Biophysical Research Communications·Marie-Claude JobinRichard P Ellen

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

© 2021 Meta ULC. All rights reserved